Zura Bio Ltd
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ZURA$1.41+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Six Months Ended June 30, | ||||||
| · 2025 · 2024 | ||||||
| Cash flows from operating activities · · · · | ||||||
| Net loss | | $(33,435) | | $(18,076) | ||
| Adjustments to reconcile net loss before redeemable noncontrolling interest to net cash used in operating activities | | | | | | |
| Share-based compensation expense | | | 7,376 | | 5,335 | |
| Change in fair value of private placement warrants | | | — | | | 1,374 |
| Depreciation and amortization | | | 20 | | 1 | |
| Foreign exchange transaction loss (gain) | | | 67 | | (25) | |
| Changes in operating assets and liabilities: | | | | | | |
| Prepaid expenses and other current assets | | | (249) | | 5 | |
| Accounts payable and accrued expenses | | | (872) | | (213) | |
| Net cash used in operating activities | | | (27,093) | | (11,599) | |
| Cash flows from investing activities | | | | | | |
| Purchase of property and equipment | | | (64) | | | (17) |
| Purchase of research and development license | | | — | | | (5,000) |
| Net cash used in investing activities | | | (64) | | (5,017) | |
| Cash flows from financing activities | | | | | | |
| Proceeds from issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions | | | 5,093 | | | — |
| Proceeds from exercise of stock options | | | 90 | | | — |
| Restricted stock units withheld to pay employee withholding taxes | | | (34) | | | — |
| Proceeds from issuance of Class A Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs | | | — | | | 55,223 |
| Proceeds from issuance of Pre-Funded Warrants in connection with April 2024 Private Placement | | | — | | 50,030 | |
| Net cash provided by financing activities | | | 5,149 | | | 105,253 |
| Net (decrease) increase in cash and cash equivalents | | | (22,008) | | | 88,637 |
| Cash and cash equivalents, beginning of period | | | 176,498 | | | 99,806 |
| Cash and cash equivalents, ending of period | | $154,490 | | $188,443 | ||
| | | | | | | |
| Supplemental Disclosure | | | | | | |
| Cash paid for taxes | | $— | | $— | ||
| Cash paid for interest | | $— | | $— | ||
| | | | | | | |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities | | | | | | |
| Adjustment of redeemable noncontrolling interest from redemption value to carrying value | | $— | | $7,017 | ||
| Accretion of redeemable noncontrolling interest to redemption value | | $— | | $2,337 | ||
| Purchase of property and equipment included in accounts payable and accrued expenses | | $12 | | $9 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.